6/4
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/30
08:54 am
atxs
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference [Yahoo! Finance]
Medium
Report
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference [Yahoo! Finance]
5/30
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
Medium
Report
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
5/24
08:12 am
atxs
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference [Yahoo! Finance]
5/24
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
Low
Report
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
5/23
08:15 am
atxs
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress [Yahoo! Finance]
5/23
08:00 am
atxs
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
Low
Report
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
5/21
08:03 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $29.00 to $25.00. They now have an "outperform" rating on the stock.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $29.00 to $25.00. They now have an "outperform" rating on the stock.
5/11
08:37 am
atxs
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate [Yahoo! Finance]
Low
Report
We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate [Yahoo! Finance]
5/10
03:42 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
5/10
11:26 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $22.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $22.00 price target on the stock.
5/9
04:24 pm
atxs
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
5/9
04:10 pm
atxs
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Medium
Report
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
5/8
08:05 am
atxs
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting [Yahoo! Finance]
Low
Report
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting [Yahoo! Finance]
5/8
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
Low
Report
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
5/2
04:00 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/23
08:09 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at HC Wainwright from $18.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target lowered by analysts at HC Wainwright from $18.00 to $16.00. They now have a "buy" rating on the stock.
4/9
08:25 am
atxs
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors [Yahoo! Finance]
Low
Report
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors [Yahoo! Finance]
4/9
08:00 am
atxs
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
Low
Report
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
4/3
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/26
09:33 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
High
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $17.00 price target on the stock.
3/26
08:13 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $27.00. They now have a "buy" rating on the stock.
High
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Jefferies Financial Group Inc. from $22.00 to $27.00. They now have a "buy" rating on the stock.
3/25
01:01 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
3/25
07:45 am
atxs
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE [Yahoo! Finance]
Medium
Report
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE [Yahoo! Finance]
3/25
07:30 am
atxs
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Medium
Report
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE